Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma
Open Access
- 3 November 2010
- Vol. 116 (22), 5200-5206
- https://doi.org/10.1002/cncr.25303
Abstract
BACKGROUND: Gemcitabine (2′,2′‐difluorodeoxycytidine) administration after resection of pancreatic cancer improves both disease‐free survival (DFS) and overall survival (OS). Deoxycytidine kinase (dCK) mediates the rate‐limiting catabolic step in the activation of gemcitabine. The authors of this report studied patient outcomes according to the expression of dCK after a postoperative gemcitabine‐based chemoradiation regimen. METHODS: Forty‐five patients with resected pancreatic adenocarcinoma received adjuvant gemcitabine based‐therapy in the context of multicenter phase 2 studies. Their tumors were evaluated retrospectively for dCK protein expression by immunohistochemistry. A composite score based on the percentage of dCK‐positive cancer cells and the intensity of staining was generated, and the results were dichotomized at the median values. RESULTS: The median follow‐up was 19.95 months (95% confident interval [CI], 3.3‐107.4 months). The lymph node (LN) ratio and dCK protein expression were significant predictors of DFS and OS in univariate analysis. On multivariate analysis, dCK protein expression was the only independent prognostic variable (DFS: hazard ratio [HR], 3.48; 95% CI, 1.66‐7.31; P = .001; OS: HR, 3.2; 95% CI,1.44‐7.13; P = .004). CONCLUSIONS: dCK protein expression was identified as an independent and strong prognostic factor in patients with resected pancreatic adenocarcinoma who received adjuvant gemcitabine therapy. The authors concluded that it deserves prospective evaluation as a predictive biomarker for patient selection. Cancer 2010. © 2010 American Cancer Society.This publication has 25 references indexed in Scilit:
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic AdenocarcinomaClinical Cancer Research, 2009
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic CancerGastroenterology, 2009
- Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomasThe Esophagus, 2007
- Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancerInternational Journal of Cancer, 2006
- Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and SurvivalClinical Cancer Research, 2006
- Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumoursJournal of Clinical Pathology, 2005
- Mammalian deoxyribonucleoside kinasesPharmacology & Therapeutics, 1995
- 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell linesBiochemical Pharmacology, 1993
- Deoxycytidine is salvaged not only into DNA but also into phospholipid precursors. III. dCDP-diacylglycerol formation in tonsillar lymphocytesBiochemical and Biophysical Research Communications, 1991
- Deoxycytidine is salvaged not only into dna but also into phospholipid precursorsBiochemical and Biophysical Research Communications, 1988